Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
CMTM4 CRISPR Activation Plasmid (h): sc-405296-ACT
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- CMTM4 CRISPR Activation Plasmid (h) is a synergistic activation mediator (SAM) transcription activation system designed to specifically upregulate gene expression
- CMTM4 CRISPR Activation Plasmid (h) consists of three plasmids at a 1:1:1 mass ratio: a plasmid encoding the deactivated Cas9 (dCas9) nuclease (D10A and N863A) fused to the transactivation domain VP64, and a blasticidin resistance gene; a plasmid encoding the MS2-p65-HSF1 fusion protein, and a hygromycin resistance gene; a plasmid encoding a target-specific 20 nt guide RNA fused to two MS2 RNA aptamers, and a puromycin resistance gene
- The resulting SAM complex binds to a site-specific region approximately 200-250 nt upstream of the transcriptional start site and provides robust recruitment of transcription factors for highly efficient gene activation
- gRNAs encoded by CMTM4 CRISPR Activation Plasmid (h) and CMTM4 CRISPR Activation Plasmid (h2) target distinct regulatory regions upstream of the CMTM4 transcriptional start site. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: CMTM4 Antibody (1E8): sc-81942
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
CMTM4 CRISPR Activation Plasmid (h) | sc-405296-ACT | 20 µg | $397.00 | |||
CMTM4 CRISPR Activation Plasmid (h2) | sc-405296-ACT-2 | 20 µg | $397.00 |
CMTM4 (CKLF-like MARVEL transmembrane domain-containing protein 4) is a multi-pass membrane protein of the CMTM family implicated in regulation of membrane organization, endosomal trafficking, and immune-related signaling. Through its MARVEL domain, CMTM4 contributes to control of surface protein stability and turnover, including modulation of PD-L1 abundance via endosome–lysosome pathways, thereby influencing cell–cell communication and immune evasion mechanisms. CMTM4 expression has been linked to cellular differentiation programs and stress responses, and altered regulation has been reported across multiple cancer contexts. These properties make CMTM4 a useful node for studying membrane trafficking, immune checkpoint regulation, and tumor–immune interactions in human model systems.
CMTM4 CRISPR Activation Plasmid (h) provides a targeted, non-destructive approach to upregulating endogenous CMTM4 expression without altering the underlying DNA sequence.
CMTM4 CRISPR Activation Plasmid (h) is a three-plasmid synergistic activation mediator (SAM) system engineered for highly efficient, site-specific transcriptional upregulation of the CMTM4 locus in human cell lines. The system is built around a catalytically inactive Cas9 (dCas9) carrying two inactivating mutations (D10A and N863A) that eliminate nuclease activity while preserving DNA binding. This dCas9 is fused to VP64, a potent transcriptional activator, and is co-expressed with a blasticidin resistance gene for selection. The second plasmid encodes the MS2-p65-HSF1 fusion protein, a secondary activator complex that works in concert with dCas9-VP64, alongside a hygromycin resistance gene. The third plasmid encodes a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers that recruit the MS2-p65-HSF1 complex to the activation site, accompanied by a puromycin resistance gene. The three plasmids are delivered at a 1:1:1 mass ratio for balanced expression of all system components.
Once assembled at the target locus, the SAM complex binds within approximately 200 bp upstream of the CMTM4 transcriptional start site, where VP64, p65, and HSF1 act in concert to recruit transcriptional machinery and drive upregulation of endogenous CMTM4 expression. Unlike nuclease-active Cas9, dCas9 does not introduce double-strand breaks or modify the genomic sequence, preserving the native CMTM4 locus and enabling the study of CMTM4-dependent transcriptional responses at the endogenous locus, making it a valuable tool for functional studies, target gene identification, and the modeling of CMTM4 pathway restoration in tumor cells with silenced or reduced CMTM4 expression.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.